Crystal Parney
|
October 31, 2023
Crystal Parney
|
October 31, 2023
Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults
Crystal Parney
|
October 31, 2023
Nation’s first dual degree in medicine and AI aims to prepare the next generation of health care providers
Crystal Parney
|
October 30, 2023